191 results
8-K
EX-99.1
DMKPQ
DMK Pharmaceuticals Corp
14 Nov 23
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
3:57pm
$1.4 million of the costs related to the acquisition of DMK and approximately $0.9 million related to increased legal expenses, offset by a decrease … million and an increase in gains recognized upon the revaluation of the warrant liabilities of $2.2 million, offset by a charge during the nine months
DEFC14A
DMKPQ
DMK Pharmaceuticals Corp
12 Oct 23
Proxy in contested solicitation
4:22pm
B-2
than stock), such expiration, termination or settlement will not reduce (or otherwise offset) the number of shares of Common Stock that may
PREC14A
DMKPQ
DMK Pharmaceuticals Corp
2 Oct 23
Preliminary proxy with contested solicitation
4:49pm
(i.e., the Participant receives cash rather
Annex B-2
than stock), such expiration, termination or settlement will not reduce (or otherwise offset
424B4
ah0mirp6midqytlfy
3 Aug 23
Prospectus supplement with pricing info
4:55pm
8-K
EX-99.1
0bo8e6oeujikhdxl
15 May 23
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:56pm
DEFA14A
4mx6iu828vos6x5i58
5 May 23
Additional proxy soliciting materials
5:27pm
DEFA14A
8x5xyj631j5am
27 Apr 23
Additional proxy soliciting materials
4:26pm
DEFM14A
tbs87sc34ec4 ukx4
13 Apr 23
Proxy related to merger
4:52pm
DEFA14A
m2owu
13 Apr 23
Additional proxy soliciting materials
4:45pm
8-K
EX-99.1
eaixpgzj
14 Nov 22
Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:27pm
DEFA14A
hjmetao0vha
18 Aug 22
Additional proxy soliciting materials
3:07pm
DEFA14A
wh8vqjlybcpt6
15 Aug 22
Additional proxy soliciting materials
6:01am